Accuray's Cancer Treatment Device CyberKnife To Expand In Japanese Market
This article was originally published in PharmAsia News
Executive Summary
With Japan's Ministry of Health, Labor and Welfare approval of CyberKnife, a cancer treatment device made by U.S. medical device maker Accuray in June, the device has been expanded from treating head and neck tumors to lung, liver, kidney, prostate and other cancers. Using image guidance technology and computer controlled robotics, the CyberKnife reduces necessary treatments from 50-70 times to only 5 times, and patients suffer less due to its painless nature and no need for anesthesia. Costing ¥600 million per unit, Accuray Japan President Mineo Kinashi said the company will apply for more insurance coverage for the treatment, and estimated that the market will increase from its current 20 units to 100 units in five years. (Click here for more - Japanese language
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.